Association of hematopoietic cell transplantation-specific comorbidity index with resource utilization after allogeneic transplantation

L. Decook, Y. H. Chang, James L Slack, D. Gastineau, J. Leis, P. Noel, Jeanne Palmer, Lisa Sproat, M. Sorror, Nandita D Khera

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Comorbidities affect clinical outcomes and costs in medicine. The hematopoietic cell transplantation (HCT)-specific comorbidity index (HCT-CI) predicts mortality risk after HCT. Its association with resource utilization (RU) is unknown. In this single-center, retrospective study, we examined the association of HCT-CI with RU (readmissions, length of hospital stay (LOS) and days out of hospital alive (Doha)) in first 100 days (n=328) and 1 year (n=226) in allogeneic HCT patients from January 2010 to June 2014. Age, disease risk, conditioning and use of antithymocyte globulin were significantly different in the four groups with HCT-CI 0 to1 (n=138), 2 (n=56), 3 (n=55) or ' 3/44 (n=79). Although the readmissions were higher in the first 100 days for patients with HCT-CI >0-1 (P=0.03), they were not significantly different in patients over 1 year (P=0.13). In the multivariable analysis, patients with HCT-CI score of >0 to 1 had increased LOS and fewer Doha in both 100 days and 1 year after HCT. In this exploratory analysis, we found that HCT-CI >0 to 1 is associated with increased RU after allogeneic HCT. Recognizing predictors of RU can identify patients at risk of high utilization and help understand what drives health-care costs.

Original languageEnglish (US)
Pages (from-to)998-1002
Number of pages5
JournalBone Marrow Transplantation
Volume52
Issue number7
DOIs
StatePublished - Jul 1 2017

Fingerprint

Cell Transplantation
Homologous Transplantation
Comorbidity
Length of Stay
Antilymphocyte Serum
Health Care Costs
Retrospective Studies
Medicine
Costs and Cost Analysis
Mortality

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Association of hematopoietic cell transplantation-specific comorbidity index with resource utilization after allogeneic transplantation. / Decook, L.; Chang, Y. H.; Slack, James L; Gastineau, D.; Leis, J.; Noel, P.; Palmer, Jeanne; Sproat, Lisa; Sorror, M.; Khera, Nandita D.

In: Bone Marrow Transplantation, Vol. 52, No. 7, 01.07.2017, p. 998-1002.

Research output: Contribution to journalArticle

@article{8d0ed80ba5774cf1942610c01a8ab061,
title = "Association of hematopoietic cell transplantation-specific comorbidity index with resource utilization after allogeneic transplantation",
abstract = "Comorbidities affect clinical outcomes and costs in medicine. The hematopoietic cell transplantation (HCT)-specific comorbidity index (HCT-CI) predicts mortality risk after HCT. Its association with resource utilization (RU) is unknown. In this single-center, retrospective study, we examined the association of HCT-CI with RU (readmissions, length of hospital stay (LOS) and days out of hospital alive (Doha)) in first 100 days (n=328) and 1 year (n=226) in allogeneic HCT patients from January 2010 to June 2014. Age, disease risk, conditioning and use of antithymocyte globulin were significantly different in the four groups with HCT-CI 0 to1 (n=138), 2 (n=56), 3 (n=55) or ' 3/44 (n=79). Although the readmissions were higher in the first 100 days for patients with HCT-CI >0-1 (P=0.03), they were not significantly different in patients over 1 year (P=0.13). In the multivariable analysis, patients with HCT-CI score of >0 to 1 had increased LOS and fewer Doha in both 100 days and 1 year after HCT. In this exploratory analysis, we found that HCT-CI >0 to 1 is associated with increased RU after allogeneic HCT. Recognizing predictors of RU can identify patients at risk of high utilization and help understand what drives health-care costs.",
author = "L. Decook and Chang, {Y. H.} and Slack, {James L} and D. Gastineau and J. Leis and P. Noel and Jeanne Palmer and Lisa Sproat and M. Sorror and Khera, {Nandita D}",
year = "2017",
month = "7",
day = "1",
doi = "10.1038/bmt.2017.70",
language = "English (US)",
volume = "52",
pages = "998--1002",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - Association of hematopoietic cell transplantation-specific comorbidity index with resource utilization after allogeneic transplantation

AU - Decook, L.

AU - Chang, Y. H.

AU - Slack, James L

AU - Gastineau, D.

AU - Leis, J.

AU - Noel, P.

AU - Palmer, Jeanne

AU - Sproat, Lisa

AU - Sorror, M.

AU - Khera, Nandita D

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Comorbidities affect clinical outcomes and costs in medicine. The hematopoietic cell transplantation (HCT)-specific comorbidity index (HCT-CI) predicts mortality risk after HCT. Its association with resource utilization (RU) is unknown. In this single-center, retrospective study, we examined the association of HCT-CI with RU (readmissions, length of hospital stay (LOS) and days out of hospital alive (Doha)) in first 100 days (n=328) and 1 year (n=226) in allogeneic HCT patients from January 2010 to June 2014. Age, disease risk, conditioning and use of antithymocyte globulin were significantly different in the four groups with HCT-CI 0 to1 (n=138), 2 (n=56), 3 (n=55) or ' 3/44 (n=79). Although the readmissions were higher in the first 100 days for patients with HCT-CI >0-1 (P=0.03), they were not significantly different in patients over 1 year (P=0.13). In the multivariable analysis, patients with HCT-CI score of >0 to 1 had increased LOS and fewer Doha in both 100 days and 1 year after HCT. In this exploratory analysis, we found that HCT-CI >0 to 1 is associated with increased RU after allogeneic HCT. Recognizing predictors of RU can identify patients at risk of high utilization and help understand what drives health-care costs.

AB - Comorbidities affect clinical outcomes and costs in medicine. The hematopoietic cell transplantation (HCT)-specific comorbidity index (HCT-CI) predicts mortality risk after HCT. Its association with resource utilization (RU) is unknown. In this single-center, retrospective study, we examined the association of HCT-CI with RU (readmissions, length of hospital stay (LOS) and days out of hospital alive (Doha)) in first 100 days (n=328) and 1 year (n=226) in allogeneic HCT patients from January 2010 to June 2014. Age, disease risk, conditioning and use of antithymocyte globulin were significantly different in the four groups with HCT-CI 0 to1 (n=138), 2 (n=56), 3 (n=55) or ' 3/44 (n=79). Although the readmissions were higher in the first 100 days for patients with HCT-CI >0-1 (P=0.03), they were not significantly different in patients over 1 year (P=0.13). In the multivariable analysis, patients with HCT-CI score of >0 to 1 had increased LOS and fewer Doha in both 100 days and 1 year after HCT. In this exploratory analysis, we found that HCT-CI >0 to 1 is associated with increased RU after allogeneic HCT. Recognizing predictors of RU can identify patients at risk of high utilization and help understand what drives health-care costs.

UR - http://www.scopus.com/inward/record.url?scp=85021788448&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021788448&partnerID=8YFLogxK

U2 - 10.1038/bmt.2017.70

DO - 10.1038/bmt.2017.70

M3 - Article

C2 - 28436978

AN - SCOPUS:85021788448

VL - 52

SP - 998

EP - 1002

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 7

ER -